Saladax Biomedical, a Bethlehem, Penn.-based privately held company that develops diagnostic assays for the practical delivery of personalized medicine, has appointed Mark D. Myslinski as senior vice president and chief commercial officer.

Myslinski has nearly 30 years of life sciences and diagnostics industry experience with Fortune 100 and venture-backed startup organizations. Most recently he served as president and CEO of RedPath Integrated Pathology, where he and the team transformed the company from a research and market development focus to full commercialization of a novel molecular diagnostic assay in a Clinical Laboratory Improvements Amendments (CLIA) certified laboratory.

Prior to his time at RedPath, Myslinski served as vice president of evidence-based medicine at Ortho Clinical Diagnostics, and general manager, molecular and cellular diagnostics division of Veridex, both of which are Johnson & Johnson companies.